Maze Therapeutics, Inc. - 8-K Filing
Amy Bachrodt will resign as Senior Vice President, Finance of Maze Therapeutics effective June 1, 2026. Her departure is not due to any disagreements with the company's operations or financial reporting. Misbah Tahir, the Chief Financial Officer, will assume the role of principal accounting officer following her resignation. (Items: 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Offi)
Tickers: $MAZE